Clinical Trial: NCT02273375
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Canadian Cancer Trials Group |
| Information Provided By: | Canadian Cancer Trials Group |
| Last Update Posted: | 2026-09-14 |
Study Overview
Brief Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Official Title
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: MEDI4736
- Drug: Placebo
Other Study ID Numbers
- BR31
- IFCT1401
- ACTRN12615000323527
- U1111-1238-5923
Start Date (Actual)
2015-02-24
Primary Completion Date (Actual)
2025-07-23
Study Completion Date (Actual)
2026-09-01
Enrollment (Actual)
1415
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Canadian Cancer Trials Group |
| Information Provided By: | Canadian Cancer Trials Group |
| Last Update Posted: | 2026-09-14 |
Study Overview
Brief Summary
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Official Title
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: MEDI4736
- Drug: Placebo
Other Study ID Numbers
- BR31
- IFCT1401
- ACTRN12615000323527
- U1111-1238-5923
Start Date (Actual)
2015-02-24
Primary Completion Date (Actual)
2025-07-23
Study Completion Date (Actual)
2026-09-01
Enrollment (Actual)
1415
Study Type
Interventional
Phase
Phase 3